Abstract
In recent years, the link between obesity, inflammation and atherosclerosis has attracted increasing interest. Recently, besides the classical inflammatory markers, the competitive nitric oxide synthase antagonist asymmetric dimethylarginine (ADMA) has been shown to be involved in the pathogenesis of atherosclerosis and cardiovascular diseases. Since obese people present a condition of chronic low-grade inflammation and endothelial dysfunction, in the present study we quantified ADMA levels in uncomplicated obese women (with no clinical, cardiac or metabolic complications) and normal-weight control subjects. We investigated the relationship of ADMA with some anthropometric measurements, abdominal visceral and subcutaneous adipose tissue accumulation, and biochemical and proinflammatory factors of the subjects [interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R), IL6-R/IL-6 ratio, tumor necrosis factor alpha (TNFα), homocysteine (Hcy) and plasminogen activator inhibitor-1 (PAI-1)]. ADMA and all the other pro-inflammatory parameters resulted higher in obese patients than in healthy subjects. ADMA significantly correlated with Hcy, PAI-1, TNFα and with sIL-6R/IL-6 ratio but not with other anthropometric and biochemical parameters. In a stepwise regression analysis ADMA correlated most closely with Hcy and TNFα. In conclusion, in our obese uncomplicated patients TNFα and Hcy emerged as strong predictors of ADMA which might be a potential mediator of the effects of different risk factors affecting the cardiovascular system.
| Original language | English |
|---|---|
| Pages (from-to) | 249-255 |
| Number of pages | 7 |
| Journal | European Journal of Inflammation |
| Volume | 9 |
| Issue number | 3 |
| Publication status | Published - Sep 2011 |
Fingerprint
Keywords
- Asymmetric dimethylarginine
- Cardiovascular risk
- Inflammation
- Obesity
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
Asymmetric dimethylarginine : Relationship with circulating biomarkers of inflammation and cardiovascular disease risk in uncomplicated obese women. / Dozio, Elena; Malavazos, A. E.; Dogliotti, G.; Goggi, S.; Galliera, E.; Solimene, U.; Magni, P.; Costa, E.; Morricone, L.; Corsi, M. M.
In: European Journal of Inflammation, Vol. 9, No. 3, 09.2011, p. 249-255.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Asymmetric dimethylarginine
T2 - Relationship with circulating biomarkers of inflammation and cardiovascular disease risk in uncomplicated obese women
AU - Dozio, Elena
AU - Malavazos, A. E.
AU - Dogliotti, G.
AU - Goggi, S.
AU - Galliera, E.
AU - Solimene, U.
AU - Magni, P.
AU - Costa, E.
AU - Morricone, L.
AU - Corsi, M. M.
PY - 2011/9
Y1 - 2011/9
N2 - In recent years, the link between obesity, inflammation and atherosclerosis has attracted increasing interest. Recently, besides the classical inflammatory markers, the competitive nitric oxide synthase antagonist asymmetric dimethylarginine (ADMA) has been shown to be involved in the pathogenesis of atherosclerosis and cardiovascular diseases. Since obese people present a condition of chronic low-grade inflammation and endothelial dysfunction, in the present study we quantified ADMA levels in uncomplicated obese women (with no clinical, cardiac or metabolic complications) and normal-weight control subjects. We investigated the relationship of ADMA with some anthropometric measurements, abdominal visceral and subcutaneous adipose tissue accumulation, and biochemical and proinflammatory factors of the subjects [interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R), IL6-R/IL-6 ratio, tumor necrosis factor alpha (TNFα), homocysteine (Hcy) and plasminogen activator inhibitor-1 (PAI-1)]. ADMA and all the other pro-inflammatory parameters resulted higher in obese patients than in healthy subjects. ADMA significantly correlated with Hcy, PAI-1, TNFα and with sIL-6R/IL-6 ratio but not with other anthropometric and biochemical parameters. In a stepwise regression analysis ADMA correlated most closely with Hcy and TNFα. In conclusion, in our obese uncomplicated patients TNFα and Hcy emerged as strong predictors of ADMA which might be a potential mediator of the effects of different risk factors affecting the cardiovascular system.
AB - In recent years, the link between obesity, inflammation and atherosclerosis has attracted increasing interest. Recently, besides the classical inflammatory markers, the competitive nitric oxide synthase antagonist asymmetric dimethylarginine (ADMA) has been shown to be involved in the pathogenesis of atherosclerosis and cardiovascular diseases. Since obese people present a condition of chronic low-grade inflammation and endothelial dysfunction, in the present study we quantified ADMA levels in uncomplicated obese women (with no clinical, cardiac or metabolic complications) and normal-weight control subjects. We investigated the relationship of ADMA with some anthropometric measurements, abdominal visceral and subcutaneous adipose tissue accumulation, and biochemical and proinflammatory factors of the subjects [interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R), IL6-R/IL-6 ratio, tumor necrosis factor alpha (TNFα), homocysteine (Hcy) and plasminogen activator inhibitor-1 (PAI-1)]. ADMA and all the other pro-inflammatory parameters resulted higher in obese patients than in healthy subjects. ADMA significantly correlated with Hcy, PAI-1, TNFα and with sIL-6R/IL-6 ratio but not with other anthropometric and biochemical parameters. In a stepwise regression analysis ADMA correlated most closely with Hcy and TNFα. In conclusion, in our obese uncomplicated patients TNFα and Hcy emerged as strong predictors of ADMA which might be a potential mediator of the effects of different risk factors affecting the cardiovascular system.
KW - Asymmetric dimethylarginine
KW - Cardiovascular risk
KW - Inflammation
KW - Obesity
UR - http://www.scopus.com/inward/record.url?scp=84858630698&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858630698&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84858630698
VL - 9
SP - 249
EP - 255
JO - European Journal of Inflammation
JF - European Journal of Inflammation
SN - 1721-727X
IS - 3
ER -